GDK PHARMACY
ActiveGDK PHARMACY has been active since 1988 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €181k and a net result of €12k. Equity remains stable across the filed fiscal years (±1.3% per year). Its solvency ranks better than 40% of 9625 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.5% (low).
Checked score
Score 2024
62
/ 100
Healthy
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability65▲+13
Solvency55▲+7
Growth52=
Track record100
Bankruptcy probability, 12 months
0.5%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €11k at 30 days acceptable
Liquidity tight (current ratio 1.26 against 1.13 in 2023; short-term debt: 69.7% and cash: 10.6% of total assets), and 69.7% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 29-08-2025, 29 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
29 d late
2023
30 d late
2022
74 d late
2021
31 d late
2020
31 d late
2019
38 d late
← before the deadline
after the deadline →
Financials · fiscal year 2024, abbreviated schema
Equity
€181k▲ 7.1%
2023 · €169k
2018: €157k
2019: €194k
2020: €195k
2021: €188k
2022: €169k
2023: €169k
2018 → 2024
Total assets
€596k▼ 17.4%
2023 · €722k
2018: €689k
2019: €747k
2020: €551k
2021: €582k
2022: €565k
2023: €722k
2018 → 2024
Net result
€12k
2023 · €-491
2018: €51k
2019: €87k
2020: €2k
2021: €-8k
2022: €-19k
2023: €-491
2018 → 2024
Working capital
€109k▲ 47.4%
2023 · €74k
2018: €72k
2019: €76k
2020: €57k
2021: €57k
2022: €49k
2023: €74k
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€195k-€188k▼ 4.0%€169k▼ 9.9%€169k▼ 0.3%€181k▲ 7.1%
Operating result€57k-€51k▼ 11.3%€-7k€11k€28k▲ 162%
Net result€2k-€-8k€-19k▼ 134%€-491▲ 97.3%€12k
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2022 the operating result has climbed two years in a row; 2024 is 162% above 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €596k
Fixed assets
€72k▼ 24.1%
Current assets
€524k▼ 16.4%
Equity and liabilities €596k
Equity
€181k▲ 7.1%
Debt
€415k▼ 24.9%
The debt ratio falls from 76.6% to 69.7%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€51k▲
2023 · €36k
Cash flow
€35k▲
2023 · €25k
Solvency
30.3%▲
2023 · 23.4%
Current ratio
1.26▲
2023 · 1.13
Quick ratio
0.69▲
2023 · 0.69
Debt / equity
2.30▼
2023 · 3.28
ROE
6.6%▲
2023 · -0.3%
ROA
2.0%▲
2023 · -0.1%
Interest coverage
5.29▲
2023 · 3.96
Debt
€415k▼
2023 · €553k
Debt ≤ 1 year
€415k▼
2023 · €553k
Income taxes
€9k▲
2023 · €3k
Staff costs
€204k▼
2023 · €224k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2024 against 2023
Balance sheet
Code20232024
Assets
Total assets20/58€722k€596k▼
Fixed assets21/28€95k€72k▼
Tangible fixed assets22/27€84k€61k▼
Plant, machinery and equipment23€84k€61k▼
Furniture and vehicles24€562-
Financial fixed assets28€11k€11k=
Current assets29/58€627k€524k▼
Stocks and contracts in progress3€246k€236k▼
Stocks30/36€246k€236k▼
Amounts receivable within one year40/41€329k€212k▼
Trade receivables40€194k€205k▲
Other amounts receivable41€135k€6k▼
Cash at bank and in hand54/58€41k€63k▲
Deferred charges and accrued income490/1€11k€13k▲
Equity and liabilities
Total equity and liabilities10/49€722k€596k▼
Equity10/15€169k€181k▲
Contributions10/11€12k€12k=
Reserves13€2k€2k=
Non-distributable reserves130/1€2k€2k=
Reserves not available under the articles1311€2k€2k=
Profit (loss) carried forward14€154k€166k▲
Amounts payable17/49€553k€415k▼
Amounts payable within one year42/48€553k€415k▼
Trade debts44€364k€284k▼
Suppliers440/4€364k€284k▼
Taxes, remuneration and social security45€21k€28k▲
Taxes450/3€4k€9k▲
Remuneration and social security454/9€17k€19k▲
Other amounts payable47/48€168k€104k▼
Income statement
Code20232024
Remuneration, social security and pensions62€224k€204k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€25k€23k▼
Other operating charges640/8€2k€622▼
Gross operating margin9900€262k€256k▼
Operating profit (loss)9901€11k€28k▲
Financial income75/76B€637€2k▲
Recurring financial income75€637€2k▲
Financial charges65/66B€9k€10k▲
Recurring financial charges65€9k€10k▲
Profit (loss) for the period before taxes9903€2k€21k▲
Income taxes67/77€3k€9k▲
Profit (loss) for the period9904€-491€12k▲
Profit (loss) for the period to be appropriated9905€-491€12k▲
Appropriation of the result
Profit (loss) to be appropriated9906€154k€166k▲
Profit (loss) brought forward from the previous period14P€155k€154k▼
Social balance
Average headcount (FTE)90873.32.8▼
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
29-08
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 29 days late
2024
31-12
Financial
Back to profitnet €12k
Net result €12k after 3 loss-making years.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 30 days late
2023
13-10
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 74 days late
2022
31-12
Financial
Weakest financial yearnet €-19k
Net result drops to €-19k, the lowest in the series; recovery starts the following year.
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 31 days late
2021
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 31 days late
2020
07-09
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 38 days late
2019
31-12
Financial
Highest result since 2018net €87k ▲70.4%
Operating result €188k, net result €87k, both a record.
30-08
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 30 days late
2018
29-08
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 29 days late
2017
31-08
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema · 31 days late
2016
30-08
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
7 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Grimbergen · 1 establishment unit since 1988
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Romeinsesteenweg 450-4521853 GrimbergenGround area
21.7 ha
Building footprint
1,250 m²
Volume, LiDAR
5,787 m³
2 parcels, Brussels, Flanders · tallest building 16.6 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
Apotheek DC Jette
since 19882.040.035.407
2 parcels
Flanders
1
(50%)
Brussels
1
(50%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21010A0012/00F003 | Brussels | 21.7 ha | 1 · 1,069 m² | 9.6 m · 1 fl. |
| 23084A0514/00W002 | Flanders | 343 m² | 1 · 181 m² | 16.6 m · 4 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
1 siteJette2.040.035.407
Similar companies · same sector, comparable size
APOTHECA
BE 0633.956.267
Sint-Joost-ten-Node · Eq €180k
PHARMACIE DE NEEF - DUEZ
BE 0445.987.390
Mons · Eq €180k
CARO PHARMA
BE 0899.338.864
Erquelinnes · Eq €180k
FARMAFLEUR
BE 0894.786.891
Antwerpen · Eq €180k
APOTHEEK TINE MARTENS
BE 0862.453.922
Hechtel-Eksel · Eq €180k
Of 5,224 companies in sector 47730 we hold annual accounts for 3,864. 3,583 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded03-08-1988
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
Sources
Crossroads Bank for EnterprisesNational Bank · 37 filingsAddress and cadastre registers
Data from official sources, last processed on 15-09-2026. Scores and ratios are computed by Checked and are not a credit decision.